DelveInsight’s, “Myopia Pipeline Insight 2024” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Myopia pipeline landscape. It covers the Myopia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Myopia therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the Myopia Pipeline. Dive into DelveInsight’s comprehensive report today! @ Myopia Pipeline Outlook
Key Takeaways from the Myopia Pipeline Report
- July 2024:- Hoffmann-La Roche– This is a Phase III, multicenter, randomized, double-masked, active comparator-controlled study evaluating the efficacy and safety of faricimab in patients with myopic choroidal neovascularization (CNV). This non-inferiority study will compare 6.0 mg faricimab versus 0.5 mg ranibizumab administered at a pro-re-nata (PRN) dosing regimen after an initial active IVT treatment administration at randomization (Day 1).
- July 2024:- VIS Inc.– The goal of this clinical trial is to evaluate the safety and efficacy of using the VIS Opti-K System to enable monovision by providing temporary improvement in near vision through the treatment of the non-dominant eye of low myopic, emmetropic and low hyperopic presbyope subjects. The main questions it aims to answer are determining uncorrected near visual acuity at 40cm in the treated eye and subjective improvement as measured by the patient satisfaction questionnaire.
- DelveInsight’s Myopia pipeline report depicts a robust space with 8+ active players working to develop 10+ pipeline therapies for Myopia treatment.
- The leading Myopia Companies such as Sydnexis, Sunhawk Vision Biotech, Vyluma, Eyenovia, Cloudbreak Therapeutics, Stuart Therapeutics, and others.
- Promising Myopia Therapies such as SYD-101 Dose 1, Alleance, NVK-002 Concentration 1, QLM3004 Concentration 1, Atropine Sulfate 01, and others.
Stay ahead with the most recent pipeline outlook for Myopia. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Myopia Treatment Drugs
Myopia Emerging Drugs Profile
- Atropine micro-formulation (MicroPine): Eyenovia
MicroPine is a proprietary microdose formulation of atropine used in our Optejet dispenser and product candidate for the prevention of progressive myopia (nearsightedness) in children. It is believed that Eyenovia’s delivery technology is particularly well-suited for this application and patient population, potentially enabling children to easily self-administer atropine medication while minimizing dose-related side effects. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Myopia.
- SYD-101: Sydnexis
SYD-101 is an investigational low-dose atropine sulfate ophthalmic solution, 0.01% and 0.03%, designed to achieve efficacy, stability, and reduce discomfort for improved treatment continuity, according to studies on the treatment of childhood myopia. While published reports have shown low concentrations of compounded atropine to be effective, these solutions are limited by short shelf life and remain only stable if markedly acidified, which can also cause excessive burning and stinging in children, according to several studies on atropine for myopia. Currently, the drug is in phase III stage of its clinical trial for the treatment of Myopia.
Explore groundbreaking therapies and clinical trials in the Myopia Pipeline. Access DelveInsight’s detailed report now! @ New Myopia Drugs
Myopia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
Myopia Products have been categorized under various Molecule types such as
- Oligonucleotide
- Peptide
- Small molecule
Unveil the future of Myopia Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Myopia Market Drivers and Barriers
Scope of the Myopia Pipeline Report
- Coverage- Global
- Myopia Companies- Sydnexis, Sunhawk Vision Biotech, Vyluma, Eyenovia, Cloudbreak Therapeutics, Stuart Therapeutics, and others.
- Myopia Therapies- SYD-101 Dose 1, Alleance, NVK-002 Concentration 1, QLM3004 Concentration 1, Atropine Sulfate 01, and others.
- Myopia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Myopia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Myopia Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Myopia Companies, Key Products and Unmet Needs
Table of Content
- Introduction
- Executive Summary
- Myopia: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Myopia – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Atropine micro-formulation (MicroPine): Eyenovia
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Drug Name: Company Name
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Drug Name: Company Name
- Drug profiles in the detailed report…..
- Preclinical Stage Products
- Drug Name: Company Name
- Drug profiles in the detailed report…..
- Inactive Products
- Myopia – Collaborations Assessment- Licensing / Partnering / Funding
- Myopia – Unmet Needs
- Myopia – Market Drivers and Barriers
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/